In depth characterization of midbrain organoids derived from wild type iPSC lines

PLoS One. 2023 Oct 20;18(10):e0292926. doi: 10.1371/journal.pone.0292926. eCollection 2023.

Abstract

The ability to model human neurological tissues in vitro has been a major hurdle to effective drug development for neurological disorders. iPSC-derived brain organoids have emerged as a compelling solution to this problem as they have the potential to relevantly model the protein expression pattern and physiology of specific brain regions. Although many protocols now exist for the production of brain organoids, few attempts have been made to do an in-depth kinetic evaluation of expression of mature regiospecific markers of brain organoids. To address this, we differentiated midbrain-specific brain organoids from iPSC-lines derived from three apparently healthy individuals using a matrix-free, bioreactor method. We monitored the expression of midbrain-specific neuronal markers from 7 to 90-days using immunofluorescence and immunohistology. The organoids were further characterized using electron microscopy and RNA-seq. In addition to serving as a potential benchmark for the future evaluation of other differentiation protocols, the markers observed in this study can be useful as control parameters to identify and evaluate the disease phenotypes in midbrain organoid derived from patient iPSC-lines with genetic neurological disorders.

Publication types

  • Research Support, N.I.H., Intramural

MeSH terms

  • Brain
  • Cell Differentiation
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Mesencephalon
  • Nervous System Diseases* / metabolism
  • Organoids / metabolism

Grants and funding

WZ received funding from the Intramural Research Program of the National Center for Advancing Translational Sciences, National Institutes of Health (https://ncats.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.